A Phase 3 interventional study of Nebulized Lidocaine and Intranasal Midazolam in Procedural Anxiety and Procedural Pain, sponsored by Hamad Medical Corporation. Status unknown at 2 sites in Qatar. Open to participants aged 6 Months to 5 Years. Per ClinicalTrials.gov, last updated 2023-03-02.
Sponsored by Hamad Medical Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing lidocaine in Pain, Procedural — 1 open to participants now, 1 under way, none of them phase 3. Lidocaine · Pain, Procedural.
Among the 11 studies testing lidocaine in Pain, Procedural, this one is the 11th largest by planned enrollment, is the only one that started in 2021, is one of 6 in phase 3, and was the 6th registered.
243 studies on the registry are indexed under Pain, Procedural; 66 are open to participants now.
Browse Pain, Procedural studies →1 of the 11 studies testing lidocaine in Pain, Procedural is open now. Recruiting first, the newest first:
Balikesir University
Ages 18–45 · Women only · Healthy volunteers
Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 29 Pain, Procedural studies recruiting now, 13 (45%) set no upper age limit and 14 (48%) stop at 75 or younger; 14 take children under 18; 5 take healthy volunteers.
This study: 6 Months to 5 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 90 across 229 interventional studies indexed under Pain, Procedural.
Median enrollment 180 across the 11 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 11 have an industry lead sponsor. The 9 most frequent:
Hamad Medical Corporation is the lead sponsor of 139 studies on the registry; 27 are open to participants now.
Hamad Medical Corporation has 2 studies filed under Pain, Procedural — fewer than ten, so there is no comparison to draw.
1 of the studies testing lidocaine in Pain, Procedural that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07792668Balikesir UniversityPain Control During Hysterosalpingography: A Three-Arm Randomized Trial | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing lidocaine in Pain, Procedural, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Nasogastric tube (NGT) is a commonly performed procedure in the Emergency Department. Although it is not a major procedure, it is usually associated with a bad experience and cause discomfort and pain in kids. This randomized controlled double-blinded double-dummy trial aims to investigate the efficacy of local topical anesthetic and/or anxiolysis for pain/anxiety related to NGT insertion. Eligible patients are children with gastroenteritis aged 6 months to 5 years requiring NGT rehydration. The intervention are 3 arms of nebulized lidocaine with midazolam compared to nebulized midazolam alone or placebo. The primary outcome is procedure-related pain assessment using the Face, Legs, Activity, Cry, and Consolability (FLACC) scale during final NGT insertion attempt.
Nasogastric tube (NGT) insertion is commonly performed in the emergency department (ED) which can cause some pain/anxiety [Shih S and Rosen P, 2018]. The pain/discomfort related to NGT insertion comes from anxiety, gagging and sensitivity of nasopharynx and oropharynx [Tapiawala SN et al, 2008]. Success rate depends on cooperation, which limits order for nasogastric tube insertion in most patients especially in non-pediatric hospitals.
The pain and anxiety associated with such procedures in kids is a source of noxious stimuli to the nervous system. Not only does pain have a negative impact on neurological development, but children whose pain has not been adequately treated in infancy or early childhood reported lower pain thresholds as adolescents and adults [Ruda M.A.et al, 2000]. If not addressed, this pain can lead to distress for children, their parents and those performing the procedures, preprocedural anxiety in the future and can result in negative long-term emotional outcomes [Blount R.L et al,2006; Brewer S.G. et al, 2006].
Nebulized 2% lidocaine at doses of 4 and 8 mg/kg has shown to be safe in infants and children, with all blood levels obtained were well below the toxic range [Gjonaj S et al, 1997]. Nebulized lidocaine in doses up to 8 mg/kg appears to be safe and gave statistically significant reduction in pain score when used before flexible bronchoscopy [Gjonaj S et al, 1997]. Nebulized/intranasal lidocaine did not seem to be of benefit when used alone in the two previous trials for NGT insertion in children [Babl FE et al,2009; Craig SS et al, 2019]. On the other hand it greatly reduced discomfort associated with NG tube in adult population [Cullen L et al, 2004]. This might be explained by the anxiety and lack of cooperation, especially in young kids, which might limit the validity of pain score during the whole procedure.
Midazolam has a controlled sedation with a quicker recovery time. The safety and tolerability profile of midazolam in pediatric patients is comparable/superior to that observed in adults [Pacifici GM, 2014]. Midazolam is a GABA receptor agonist providing anxiolysis for procedures in pediatric population. Midazolam has been shown to be safe and effective for use in children [Wilton NC et al,1988; Theroux MC et al, 1993]. Intranasal midazolam has shown improvements with anxiety and crying, as well as need for restraint [Theroux MC et al, 1993]. Midazolam anxiolysis has been tried in pediatrics and ordered as nebulization, found to have a plasma concentration bioavailability which is comparable to the intranasal midazolam by the ratio (nebulized:nasal) of 1:2.9. [McCormick AS et al, 2008]. Clinically effective serum concentrations of intranasal midazolam can be reached within less than 10 min after nasal application [Knoester PD et al, 2002].
Lidocaine / Midazolam has been commonly used in different procedures in pediatric emergency department; such as urethral catheterization, intravenous cannulation, lumbar puncture with a great safety margin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1 Previously healthy children 6 months to 5 years old presenting with AGE and some dehydration who were planned to have a nasogastric tube inserted as part of their ED treatment.
Exclusion Criteria:
Nebulized 2% lidocaine hydrochloride 4 mg/kg to be delivered via nebulization (up to a maximum of 15 ml) and given over ½ hr. Intranasal midazolam 0.5 mg/kg delivered via intranasal atomization (up to a maximum of 10 mg).
Drug: Nebulized Lidocaine · Drug: Intranasal Midazolam
Intranasal midazolam 0.5 mg/kg to be delivered via intranasal atomization (up to a maximum of 10 mg). Nebulized placebo (Normal saline) in a volume comparable to 2% lidocaine at 4 mg/kg (up to a maximum of 15 ml) and given over ½ hr.
Drug: Intranasal Midazolam
Intranasal placebo (normal saline) in a volume comparable to midazolam 0.5 ml/kg to be delivered via intranasal atomization Nebulized placebo (Normal saline) in a volume comparable to 2% lidocaine at 4 mg/kg (up to a maximum of 15 ml) and given over ½ hr.
Other: Placebo
Nebulized Lidocaine for Reducing Pain of Nasogastric Tube Insertion in Children
Also known as: Nebulized Xylocaine
Intranasal Midazolam for reducing anxiety of Nasogastric Tube insertion
Also known as: IN Midazolam
Nebulized normal saline and intranasal normal sline
Pain severity rating scale (FLACC) during insertion of NGT.
score from 0 to 10. Higher scores mean worse outcome
Time frame: 1 year
Observer/caregiver pain severity rating:
Score from 1 to 100. Higher scores mean worse outcome
Time frame: 1 year
The ease of procedure: difficulty of insertion on an ordinal scale from 1 to 5, where 5 is the most difficult insertion.
Score from 1 to 5. Higher scores mean worse outcome
Time frame: 1 year
The number of attempts required to successfully insert the NGT
The number of attempts of successful NGT insertion
Time frame: 1 year
Procedural complications/adverse events.
Records complications and adverse effects
Time frame: 1 year
FLAC score at 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes and 180 minutes post insertion.
Scores from 0 to 10. Higher scores mean worse outcome
Time frame: up to 180 minutes
Length of stay in ED
Length of stay in minutes
Time frame: up to 180 minutes
Duration of NGT feed.
The observer records data on chart
Time frame: up to 180 minutes
Tolerated volume of NGT feed.
Amount of fluid (ml)
Time frame: 1 year
Started Aug 2021 (actual). Primary completion is estimated for Dec 2023, 28 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lidocaine · Midazolam